[1] Li PK, Szeto CC, Piraino B, et al. ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment[J]. Perit Dial Int, 2016, 36(5): 481-508.
[2] 中国腹膜透析相关感染防治专家组. 腹膜透析相关感染的防治指南[J]. 中华肾脏病杂志, 2018, 34(2): 139-148.
[3] Cho Y, Johnson DW. Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes[J]. Am J Kidney Dis, 2014, 64(2): 278-289.
[4] Li PK, Chow KM. Infectious complications in dialysis--epidemiology and outcomes[J]. Nat Rev Nephrol, 2011, 8(2): 77-88.
[5] Zelenitsky SA, Howarth J, Lagacé-Wiens P, et al. Microbiological Trends and Antimicrobial Resistance in Peritoneal Dialysis-Related Peritonitis, 2005 to 2014[J]. Perit Dial Int, 2017, 37(2): 170-176.
[6] Wong SS, Ho PL, Yuen KY. Evolution of antibiotic resistance mechanisms and their relevance to dialysis-related infections[J]. Perit Dial Int, 2007,27 Suppl 2(2): S272-280.
[7] Chao CT, Lee SY, Yang WS, et al. Viridans streptococci in peritoneal dialysis peritonitis: clinical courses and long-term outcomes[J]. Perit Dial Int, 2015, 35(3): 333-341.
[8] Zalunardo NY, Rose CL, Ma IW, et al. Higher serum C-reactive protein predicts short and long-term outcomes in peritoneal dialysis-associated peritonitis[J]. Kidney Int, 2007, 71(7): 687-692.
[9] Wang HH, Huang CH, Kuo MC, et al. Microbiology of peritoneal dialysis-related infection and factors of refractory peritoneal dialysis related peritonitis: A ten-year single-center study in Taiwan[J]. J Microbiol Immunol Infect, 2019, 52(5): 752-759.
[10] Barretti P, Montelli AC, Batalha JE, et al. The role of virulence factors in the outcome of staphylococcal peritonitis in CAPD patients[J]. BMC Infect Dis, 2009, 9(1): 212-212.
[11] Govindarajulu S, Hawley CM, McDonald SP, et al. Staphylococcus aureus peritonitis in Australian peritoneal dialysis patients: predictors, treatment, and outcomes in 503 cases[J]. Perit Dial Int, 2010, 30(3): 311-319.
[12] Szeto CC, Chow KM, Kwan BC, et al. Staphylococcus aureus peritonitis complicates peritoneal dialysis: review of 245 consecutive cases[J]. Clin J Am Soc Nephrol, 2007, 2(2): 245-251.
[13] Dasgupta MK, Kowalewaska-Grochowska K, Costerton JW. Biofilm and peritonitis in peritoneal dialysis[J]. Perit Dial Int, 1993,30(13 Suppl 2): S322-325.
[14] Finkelstein ES, Jekel J, Troidle L, et al. Patterns of infection in patients maintained on long-term peritoneal dialysis therapy with multiple episodes of peritonitis[J]. Am J Kidney Dis, 2002, 39(6): 1278-1286.
[15] Grothe C, Taminato M, Belasco A, et al. Prophylactic treatment of chronic renal disease in patients undergoing peritoneal dialysis and colonized by Staphylococcus aureus: a systematic review and meta-analysis[J]. BMC Nephrol, 2016, 17(1): 115.
[16] 刘聪慧, 周晶晶, 史亚男, 等. 腹膜透析患者难治性腹膜炎的危险因素分析[J]. 中国血液净化, 2019, 18(4): 226-230.
[17] Yang CY, Chen TW, Lin YP, et al. Determinants of catheter loss following continuous ambulatory peritoneal dialysis peritonitis[J]. Perit Dial Int, 2008, 28(4): 361-370.
[18] Ram R, Swarnalatha G, Rao CS, et al. Risk factors that determine removal of the catheter in bacterial peritonitis in peritoneal dialysis[J]. Perit Dial Int, 2014, 34(2): 239-243.
[19] 杨志凯, 周正飞, 董捷, 等. 伴外科并发症的腹膜透析腹膜炎11例及文献复习[J]. 中国血液净化, 2017, 16(4): 255-257.
[20] Moon SJ, Han SH, Kim DK, et al. Risk factors for adverse outcomes after peritonitis-related technique failure[J]. Perit Dial Int, 2008, 28(4): 352-360.
[21] Chow KM, Szeto CC, Cheung KK, et al. Predictive value of dialysate cell counts in peritonitis complicating peritoneal dialysis[J]. Clin J Am Soc Nephrol, 2006, 1(4): 768-773.
[22] Krishnan M, Thodis E, Ikonomopoulos D, et al. Predictors of outcome following bacterial peritonitis in peritoneal dialysis[J]. Perit Dial Int, 2002, 22(5): 573-581.
[23] Ye H, Zhou Q, Fan L, et al. The impact of peritoneal dialysis-related peritonitis on mortality in peritoneal dialysis patients[J]. BMC Nephrol, 2017, 18(1): 186.
[24] 易春燕, 阳晓, 郭群英, 等. 长腹膜透析龄患者首次腹膜炎的临床特征分析[J]. 中华肾脏病杂志, 2011, 27(10): 715-719.
[25] Bartosova M, Schaefer B, Vondrak K, et al. Peritoneal Dialysis Vintage and Glucose Exposure but Not Peritonitis Episodes Drive Peritoneal Membrane Transformation During the First Years of PD[J]. Front Physiol, 2019, 10: 356.
[26] Brulez HF, Verbrugh HA. First-line defense mechanisms in the peritoneal cavity during peritoneal dialysis[J]. Perit Dial Int, 1995, 15(7 Suppl): 33-34.
[27] Monteón F, Correa-Rotter R, Paniagua R, et al. Prevention of peritonitis with disconnect systems in CAPD: a randomized controlled trial. The Mexican Nephrology Collaborative Study Group[J]. Kidney Int, 1998, 54(6): 2123-2128.
[28] Srivastava S, Hildebrand S, Fan SL. Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique survival[J]. Kidney Int, 2011, 80(9): 986-991.
[29] Lewis S, Holmes C. Host defense mechanisms in the peritoneal cavity of continuous ambulatory peritoneal dialysis patients. 1[J]. Perit Dial Int, 1991, 11(1): 14-21.
[30] Han SH, Lee SC, Ahn SV, et al. Reduced residual renal function is a risk of peritonitis in continuous ambulatory peritoneal dialysis patients[J]. Nephrol Dial Transplant, 2007, 22(9): 2653-2658.
[31] Li ZJ, An X, Mao HP, et al. Association between depression and malnutrition-inflammation complex syndrome in patients with continuous ambulatory peritoneal dialysis[J]. Int Urol Nephrol, 2011, 43(3): 875-882.
[32] Mehrotra R, Devuyst O, Davies SJ, et al. The Current State of Peritoneal Dialysis[J]. J Am Soc Nephrol, 2016, 27(11): 3238-3252.
